Grasp the latest information from Olin and understand the new trends in the industry.
Recently, the Recombinant Five-antigen Staphylococcus Aureus Vaccine (rFSAV), a Class 1.1 New Drug co-developed by Chengdu Olymvax Biopharmaceuticals Inc.
Feb 18th 2025, Olymvax and Griffith University of Australia held a signing ceremony in Chengdu for their collaboration on the GAS project and contract manufacturing of GAS vaccine.
On October 13, Shanghai Stock Exchange and China Securities Index Co., Ltd. officially announced the release arrangement of the SSE STAR Growth Index (referred to as STAR Growth). As one of two selected enterprises in Sichuan,...
Recently, the China National Intellectual Property Administration publicized the evaluation results of the 2022 National Enterprises with Advantage in IPRs and Demonstration Enterprises,...
Vaccines have played an irreplaceable role from vaccinia vaccination against smallpox in the 18th century in England to the national prevention and control of pandemic diseases typified by COVID-19 in the 21st century.
On July 6, 2022, Chengdu XENOMIX Biotechnology Co., Ltd. (hereinafter referred to as “XENOMIX”), a wholly-owned subsidiary of Chengdu Olymvax Biopharmaceuticals Inc., and Lanzhou Bailing Bio-Tech Company Limited (hereinafter referred to as “Bailing Bio-Tech”) held a signing ceremony for the cell-based influenza vaccine project in Chengdu.
On June 6, 2022, the Phase III Clinical Trial Kick-off Meeting of Recombinant Staphylococcus Aureus Vaccine (RSAV) (hereinafter referred to as “Staphylococcus Aureus Vaccine”), jointly developed by Chengdu Olymvax Biopharmaceuticals Inc.